FDA approves Pfizer’s RSV shot for older adults, teeing up a competitive $17B vaccine market

Andrew Dunn

Biopharma Correspondent

The FDA approved Pfizer’s RSV vaccine called Abrysvo for older adults on Wednesday, placing another Big Pharma onto the commercial stage ahead of the next RSV season.

Pfizer’s approval comes weeks after GSK won approval for its rival shot, Arexvy. Those two vaccines are both approved for use in adults 60 years and older and will be reviewed by a CDC panel in June before they’re expected to commercially launch this fall. Wall Street analysts see RSV as the next multibillion-dollar vaccine market, with Jefferies analysts recently forecasting the RSV market will grow to $17 billion over the next decade.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

FDA approves Pfizer’s RSV shot for older adults, teeing up a competitive $17B vaccine market

Andrew Dunn

Biopharma Correspondent

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

FDA ap­proves Pfiz­er’s RSV shot for old­er adults, tee­ing up a com­pet­i­tive $17B vac­cine mar­ket

Andrew Dunn

Biopharma Correspondent

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

FDA approves Pfizer’s RSV shot for older adults, teeing up a competitive $17B vaccine market

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them